BI drug gets priority review

Share this content:

The FDA bestowed priority review status on Boehringer Ingelheim's experimental idiopathic pulmonary fibrosis treatment nintedanib. The treatment also has orphan drug status—the progressive and fatal lung disease is a rare condition which affects around 132,000 patients in the US.

Share this content:
Scroll down to see the next article